{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:23:49Z","timestamp":1707524629070},"reference-count":36,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,16]]},"DOI":"10.7759\/cureus.28066","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T16:01:32Z","timestamp":1660665692000},"source":"Crossref","is-referenced-by-count":0,"title":["COVID-19 Vaccine Clinical Trials: A Bird\u2019s Eye Perspective"],"prefix":"10.7759","author":[{"given":"Pujitha","family":"Vallivedu Chennakesavulu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaurav Venkat","family":"Cuddapah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayura Reddy","family":"Keesara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyothik Varun","family":"Inampudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amulya","family":"Arremsetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushma","family":"Moka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swamy","family":"Miryala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-020-10070-3","article-title":"A rapid review of the impact of COVID-19 on the mental health of healthcare workers: implications for supporting psychological well-being","volume":"21","author":"De Kock JH","year":"2021","unstructured":"De Kock JH, Latham HA, Leslie SJ, et al.. A rapid review of the impact of COVID-19 on the mental health of healthcare workers: implications for supporting psychological well-being. BMC Public Health. 2021, 21:104. 10.1186\/s12889-020-10070-3","journal-title":"BMC Public Health"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe0948","article-title":"Prospects for a safe COVID-19 vaccine","volume":"12","author":"Haynes BF","year":"2020","unstructured":"Haynes BF, Corey L, Fernandes P, et al.. Prospects for a safe COVID-19 vaccine. Sci Transl Med. 2020, 12:0948. 10.1126\/scitranslmed.abe0948","journal-title":"Sci Transl Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32137-1","article-title":"SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates","volume":"396","author":"Poland GA","year":"2020","unstructured":"Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020, 396:1595-606. 10.1016\/S0140-6736(20)32137-1","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 vaccines at pandemic speed","volume":"382","author":"Lurie N","year":"2020","unstructured":"Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. N Engl J Med. 2020, 382:1969-73. 10.1056\/NEJMp2005630","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1\u00a0nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen N","year":"2020","unstructured":"van Doremalen N, Lambe T, Spencer A, et al.. ChAdOx1\u00a0nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020, 586:578-82. 10.1038\/s41586-020-2608-y","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey M","year":"2021","unstructured":"Voysey M, Clemens SA, Madhi SA, et al.. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021, 397:99-111. 10.1016\/S0140-6736(20)32661-1","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000519456","article-title":"Adverse events following AstraZeneca COVID-19 vaccine in Saudi Arabia: a cross-sectional study among healthcare and nonhealthcare workers","volume":"65","author":"Alghamdi AA","year":"2022","unstructured":"Alghamdi AA, Alkazemi A, Alissa A, Alghamdi I, Alwarafi G, Waggas HA. Adverse events following AstraZeneca COVID-19 vaccine in Saudi Arabia: a cross-sectional study among healthcare and nonhealthcare workers. Intervirology. 2022, 65:104-9. 10.1159\/000519456","journal-title":"Intervirology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32623-4","article-title":"Oxford-AstraZeneca COVID-19 vaccine efficacy","volume":"397","author":"Knoll MD","year":"2021","unstructured":"Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021, 397:72-4. 10.1016\/S0140-6736(20)32623-4","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates","volume":"383","author":"Walsh EE","year":"2020","unstructured":"Walsh EE, Frenck RW Jr, Falsey AR, et al.. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N Engl J Med. 2020, 383:2439-50. 10.1056\/NEJMoa2027906","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack FP","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, et al.. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020, 383:2603-15. 10.1056\/NEJMoa2034577","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7032e4","article-title":"Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the Advisory Committee on Immunization Practices - United States","volume":"70","author":"Rosenblum HG","year":"2021","unstructured":"Rosenblum HG, Hadler SC, Moulia D, et al.. Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the Advisory Committee on Immunization Practices - United States. MMWR Morb Mortal Wkly Rep. 2021, 70:1094-9. 10.15585\/mmwr.mm7032e4","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/encyclopedia2010028","article-title":"Adverse events profile of COVID-19 preventative strategies","volume":"2","author":"Ajmera KM","year":"2022","unstructured":"Ajmera KM. Adverse events profile of COVID-19 preventative strategies. Encyclopedia. 2022, 2:457-65. 10.3390\/encyclopedia2010028","journal-title":"Encyclopedia"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2020.12.014","article-title":"Are the emerging SARS-COV-2 mutations friend or foe?","volume":"230","author":"Erol A","year":"2021","unstructured":"Erol A. Are the emerging SARS-COV-2 mutations friend or foe?. Immunol Lett. 2021, 230:63-4. 10.1016\/j.imlet.2020.12.014","journal-title":"Immunol Lett"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103553","article-title":"Lipid nanoparticles in the development of mRNA vaccines for COVID-19","volume":"74","author":"Wilson B","year":"2022","unstructured":"Wilson B, Geetha KM. Lipid nanoparticles in the development of mRNA vaccines for COVID-19. J Drug Deliv Sci Technol. 2022, 74:103553. 10.1016\/j.jddst.2022.103553","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"383","author":"Corbett KS","year":"2020","unstructured":"Corbett KS, Flynn B, Foulds KE, et al.. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med. 2020, 383:1544-55. 10.1056\/NEJMoa2024671","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2032195","article-title":"Durability of responses after SARS-CoV-2 mRNA-1273 vaccination","volume":"384","author":"Widge AT","year":"2021","unstructured":"Widge AT, Rouphael NG, Jackson LA, et al.. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021, 384:80-2. 10.1056\/NEJMc2032195","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden LR","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, et al.. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021, 384:403-16. 10.1056\/NEJMoa2035389","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a Phase 1-2A trial of Ad26.COV2.S COVID-19 vaccine","volume":"384","author":"Sadoff J","year":"2021","unstructured":"Sadoff J, Le Gars M, Shukarev G, et al.. Interim results of a Phase 1-2A trial of Ad26.COV2.S COVID-19 vaccine. N Engl J Med. 2021, 384:1824-35. 10.1056\/NEJMoa2034201","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20653-8","article-title":"SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice","volume":"12","author":"Tian JH","year":"2021","unstructured":"Tian JH, Patel N, Haupt R, et al.. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021, 12:372. 10.1038\/s41467-020-20653-8","journal-title":"Nat Commun"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103055","article-title":"Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant","volume":"384","author":"Shinde V","year":"2021","unstructured":"Shinde V, Bhikha S, Hoosain Z, et al.. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021, 384:1899-909. 10.1056\/NEJMoa2103055","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath PT","year":"2021","unstructured":"Heath PT, Galiza EP, Baxter DN, et al.. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021, 385:1172-83. 10.1056\/NEJMoa2107659","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech C","year":"2020","unstructured":"Keech C, Albert G, Cho I, et al.. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020, 383:2320-32. 10.1056\/NEJMoa2026920","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang Y","year":"2021","unstructured":"Zhang Y, Zeng G, Pan H, et al.. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect Dis. 2021, 21:181-92. 10.1016\/S1473-3099(20)30843-4","journal-title":"Lancet Infect Dis"},{"key":"ref24","unstructured":"Efficacy and safety of a COVID\u201019 inactivated vaccine in healthcare professionals in Brazil. the PROFISCOV study. (2021). Accessed: April 11, 2021: https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=3822780."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1920274","article-title":"Reactive arthritis after COVID-19 vaccination","volume":"17","author":"An QJ","year":"2021","unstructured":"An QJ, Qin DA, Pei JX. Reactive arthritis after COVID-19 vaccination. Hum Vaccin Immunother. 2021, 17:2954-6. 10.1080\/21645515.2021.1920274","journal-title":"Hum Vaccin Immunother"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-020-00821-0","article-title":"Shelter from the cytokine storm: pitfalls and prospects in the development of SARS-CoV-2 vaccines for an elderly population","volume":"42","author":"Ciabattini A","year":"2020","unstructured":"Ciabattini A, Garagnani P, Santoro F, Rappuoli R, Franceschi C, Medaglini D. Shelter from the cytokine storm: pitfalls and prospects in the development of SARS-CoV-2 vaccines for an elderly population. Semin Immunopathol. 2020, 42:619-34. 10.1007\/s00281-020-00821-0","journal-title":"Semin Immunopathol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2030033","article-title":"Trustworthiness before trust - COVID-19 vaccine trials and the black community","volume":"383","author":"Warren RC","year":"2020","unstructured":"Warren RC, Forrow L, Hodge DA Sr, Truog RD. Trustworthiness before trust - COVID-19 vaccine trials and the black community. N Engl J Med. 2020, 383:e121. 10.1056\/NEJMp2030033","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-021-01402-z","article-title":"SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges","volume":"90","author":"Cooper DM","year":"2021","unstructured":"Cooper DM, Afghani B, Byington CL, et al.. SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges. Pediatr Res. 2021, 90:966-70. 10.1038\/s41390-021-01402-z","journal-title":"Pediatr Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23353","article-title":"Antibody responses to BNT162b2 mRNA vaccine: infection-na\u00efve individuals with abdominal obesity warrant attention","volume":"30","author":"Malavazos AE","year":"2022","unstructured":"Malavazos AE, Basilico S, Iacobellis G, et al.. Antibody responses to BNT162b2 mRNA vaccine: infection-na\u00efve individuals with abdominal obesity warrant attention. Obesity (Silver Spring). 2022, 30:606-13. 10.1002\/oby.23353","journal-title":"Obesity (Silver Spring)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI147553","article-title":"COVID-19 vaccine testing in pregnant females is necessary","volume":"131","author":"Klein SL","year":"2021","unstructured":"Klein SL, Creisher PS, Burd I. COVID-19 vaccine testing in pregnant females is necessary. J Clin Invest. 2021, 131:147553. 10.1172\/JCI147553","journal-title":"J Clin Invest"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine","volume":"385","author":"Falsey AR","year":"2021","unstructured":"Falsey AR, Sobieszczyk ME, Hirsch I, et al.. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine. N Engl J Med. 2021, 385:2348-60. 10.1056\/NEJMoa2105290","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07239-z","article-title":"Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2","volume":"22","author":"Pattni K","year":"2022","unstructured":"Pattni K, Hungerford D, Adams S, et al.. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2. BMC Infect Dis. 2022, 22:270. 10.1186\/s12879-022-07239-z","journal-title":"BMC Infect Dis"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1126\/science.abg6105","article-title":"Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera","volume":"371","author":"Muik A","year":"2021","unstructured":"Muik A, Wallisch AK, S\u00e4nger B, et al.. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science. 2021, 371:1152-3. 10.1126\/science.abg6105","journal-title":"Science"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2020.12.0140.12.014","article-title":"Are the emerging SARS-COV-2 mutations friend or foe?","volume":"230","author":"Erol A","year":"2021","unstructured":"Erol A. Are the emerging SARS-COV-2 mutations friend or foe?. Immunol Lett. 2021, 230:63-4. 10.1016\/j.imlet.2020.12.0140.12.014","journal-title":"Immunol Lett"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","author":"Wang Z","year":"2021","unstructured":"Wang Z, Schmidt F, Weisblum Y, et al.. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021, 592:616-22. 10.1038\/s41586-021-03324-6","journal-title":"Nature"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1790","article-title":"Developing a vaccine for covid-19","volume":"369","author":"Caddy S","year":"2020","unstructured":"Caddy S. Developing a vaccine for covid-19. BMJ. 2020, 369:m1790. 10.1136\/bmj.m1790","journal-title":"BMJ"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/85272-covid-19-vaccine-clinical-trials-a-birds-eye-perspective","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:38:10Z","timestamp":1707507490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/85272-covid-19-vaccine-clinical-trials-a-birds-eye-perspective"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":36,"URL":"https:\/\/doi.org\/10.7759\/cureus.28066","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,16]]}}}